Sanofi Consumer Healthcare India Ltd
Sanofi Consumer Healthcare India Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #24 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q3 FY26 call signalled
2 of 3 strong
The short version
Focus is on growth and penetration in India, aiming to increase volumes and market reach.
From Sanofi Consumer Healthcare India Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Focus is on growth and penetration in India, aiming to increase volumes and market reach.
- Sustainable, profitable growth is the agenda, balancing top line, market share, and bottom line.
- Innovation and new product launches (e.g., Allegra D) are key pillars for future growth.
- Significant investment has begun since Q2 2025 into brand building, digital engagement, and expanding consumer reach.
- Expansion plans include increasing healthcare professional (HCP) reach, especially in underpenetrated regions like the East.
- The sales force of ~350 medical reps is expected to improve productivity and possibly expand depending on business case analysis.
- Inorganic growth opportunities are being explored cautiously with global support.
2 more points from Sanofi Consumer Healthcare India Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sanofi Consumer Healthcare India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Sanofi Consumer Healthcare India Limited is focused on smart and disciplined capital spending.
- Investments are targeted in the right places with high focus, avoiding indiscriminate spending.
- Performance analytics teams work on optimizing productivity and efficiency, especially in the sales force.
- The company is evaluating different reach models including digital and Omni-channel approaches before deciding on expanding the sales force.
- There is a clear intent on sustainable, profitable growth with increased investments in brand building and digital marketing started since Q2 of the previous year, which will continue.
- The organization benefits from strong local manufacturing capabilities, reducing dependency on global supplies, thus controlling capital deployment in supply chain.
2 more points from Sanofi Consumer Healthcare India Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sanofi Consumer Healthcare India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Focus is on rebuilding sales run rates close to pre-recall levels.
- Emphasis on increasing reach to healthcare practitioners (HCPs) and improving sales force productivity.
- Innovation pipeline and new product launches (e.g., Allegra D) are highlighted as growth drivers.
- Discussions on business growth with a focus on profitability, market share, and penetration, but no direct comment on order backlog status.
Sanofi Consumer Healthcare India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹263 Cr, net profit ₹77 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sanofi Consumer Healthcare India Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sanofi Consumer Healthcare India Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sanofi Consumer Healthcare India Ltd Q3 FY26 results?
Focus is on growth and penetration in India, aiming to increase volumes and market reach.
What is Sanofi Consumer Healthcare India Ltd share price analysis?
Sanofi Consumer Healthcare India Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 38.5 with a market cap of ₹10,237 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sanofi Consumer Healthcare India Ltd planning capital expenditure?
Sanofi Consumer Healthcare India Limited is focused on smart and disciplined capital spending.
Keep Sanofi Consumer Healthcare India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.